

Fourth John Vane Memorial Symposium on Prostacyclin Science and Pulmonary Vascular Disease

Supported by an unrestricted educational grant from United Therapeutics



27-28 March 2009, Royal Society, London, UK

Royal Society, 6-9 Carlton House Terrace, London, SW1Y 5AG

Session Chairs

Professor Sheila G Haworth, CBE, London, UK
Professor Robert Naeije, Brussels, Belgium

Professor Andrew Peacock, Glasgow, UK
Professor Marc Humbert, Paris, France

Faculty Chair

Professor Sir Magdi Yacoub, FRS, The Magdi Yacoub Institute, Imperial College, London, UK

Awarded 11 CPD credits by the Royal College of Physicians

WILLIAM HARVEY CONFERENCES

 **United
Therapeutics**
CORPORATION
Medicines for Life

9-10am Registration, tea and coffee

10am Welcome

Basic Science I: Pharmacology of Prostacyclin and New Therapeutic Approaches

Chairs: *Marc Humbert, Université Paris-Sud, Paris, France and Sheila G Haworth CBE, University College London, London, UK*

10.10am John Vane – Life and Science
Rod Flower, William Harvey Research Institute, London, UK

10.40am Discovery and Biology of Treprostinil
Brendan Whittle, William Harvey Research Institute, London, UK

11.10am Survival in Patients with Idiopathic PAH in the Modern Management Era
Marc Humbert, Université Paris-Sud, Paris, France

11.40am Refreshments

12.00pm Therapeutic Utility of PPAR β/δ Agonists in Preclinical Models of Pulmonary Hypertension
Jane Mitchell, Imperial College, London, UK

12.30pm Mitochondria and PAH - a Warburg Hypothesis for the Mechanism of Pulmonary Arterial Hypertension
Stephen L. Archer, University of Chicago, Illinois, USA

1pm Lunch

Clinical Science I: Clinical Developments in PAH

Chairs: *Sheila G Haworth CBE, University College London, London, UK and Marc Humbert, Université Paris-Sud, Paris, France*

2pm Pathobiology of Pulmonary Hypertension in Children: How Logical are our Treatment Strategies?
Sheila G Haworth CBE, Institute of Child Health, University College London, London, UK

2.30pm The Effect of Targeted PAH Treatments on Morbidity and Mortality
Nazzareno Galiè, University of Bologna, Bologna, Italy

3pm The Utility of Hemodynamic Monitoring in the Diagnosis and Therapy of Pulmonary Vascular Disease
Robert Bourge, University of Alabama, Birmingham, USA

3.30pm Refreshments

3.50pm Timing of Prostanoid Therapy for PAH
Irene Lang, Medical University of Vienna, Vienna, Austria

4.20pm **Debate:** Should Combination Therapy be the Goal?
Moderator: *Nick Ross* **Panel:** *Marc Humbert, Robert Naeije, Robert Bourge, Simon Gibbs*

5.20pm Adjournment

7.30pm Conference Dinner

Basic Science II: Pathophysiology and Therapy of PAH

Chairs: *Robert Naeije, Erasme University Hospital, Belgium and Andrew Peacock, Scottish Pulmonary Vascular Unit, Scotland*

- | | |
|----------------|--|
| 9.30am | The Limit of Human Tolerance of Hypoxaemia: Observations from the Xtreme Everest Expedition 2007
Monty Mythen, University College London, London, UK |
| 10am | Right Ventricular Function in PAH
Robert Naeije, Erasme University Hospital, Brussels, Belgium |
| 10.30am | Tissue Factor and Thrombin Signaling in PAH: It's More Than Just Clot
Jim White, University of Rochester Medical Center, New York, USA |
| 11am | Refreshments |
| 11.30am | Bridging to Transplant - New Approaches
James Lordan, Freeman Hospital, Newcastle-upon-Tyne, UK |
| 12pm | Long Term Outcome of PAH Therapy – The Past and the Future
Marion Delcroix, Gasthuisberg University Hospital, Leuven, Belgium |
| 12.30pm | Lunch |

Clinical Science II: Clinical Developments in PAH

Chairs: *Andrew Peacock, Scottish Pulmonary Vascular Unit, Scotland and Robert Naeije, Erasme University Hospital, Belgium*

- | | |
|---------------|---|
| 1.30pm | Pulmonary Hypertension and Left Ventricular Dysfunction
Yochai Adir, Carmel Medical Center, Haifa, Israel |
| 2pm | Translating the Message of BMP in Pulmonary Hypertension
Sean Gaine, University College Dublin, Dublin, Ireland |
| 2.30pm | Refreshments |
| 3pm | Pulmonary Hypertension in ESRD Patients
Mordechai Yigla, Rambam Medical Center, Haifa, Israel |
| 3.30pm | Update on the Outcome of the 4th World Symposium on PAH
Lewis Rubin, University of California, San Diego, USA |
| 4pm | Summary and Outlook
Andrew Peacock, Scottish Pulmonary Vascular Unit, Glasgow, Scotland |
| 4.30pm | Close |